Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two innovative drugs, SHR-A2102 and Adebali monoclonal antibody injection, indicating progress in its oncology pipeline [1] Group 1: Drug Development - SHR-A2102 is a targeted antibody-drug conjugate (ADC) developed by the company, specifically targeting Nectin-4, which is associated with tumor progression and poor prognosis [1] - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [1] - Adebali monoclonal antibody injection (brand name: Ailili) was approved for market in March 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [1]